Carisma Therapeutics Files Proxy Statement
Ticker: CARM · Form: DEFA14A · Filed: Jul 31, 2025 · CIK: 1485003
Sentiment: neutral
Topics: proxy-statement, regulatory-filing
TL;DR
Carisma Therapeutics (formerly Sesen Bio) filed its proxy statement, standard procedure, no fee.
AI Summary
Carisma Therapeutics Inc. filed a Definitive Proxy Statement (DEFA14A) on July 31, 2025. This filing is related to the company's proxy materials and does not involve a fee, as indicated by the 'No fee required' checkbox. The company was formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc.
Why It Matters
This filing is a standard regulatory requirement for public companies to provide shareholders with information regarding company matters, typically for upcoming meetings or votes.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain information about new risks or significant financial events.
Key Players & Entities
- Carisma Therapeutics Inc. (company) — Registrant
- Sesen Bio, Inc. (company) — Former company name
- Eleven Biotherapeutics, Inc. (company) — Former company name
- 2674916422 (phone_number) — Business phone number
FAQ
What type of filing is this?
This is a Definitive Proxy Statement (DEFA14A).
Who is the registrant?
The registrant is Carisma Therapeutics Inc.
When was this filing submitted?
The filing was submitted on July 31, 2025.
Does this filing require a fee?
No fee is required for this filing.
What were Carisma Therapeutics Inc.'s former names?
Carisma Therapeutics Inc. was formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on July 31, 2025 regarding Carisma Therapeutics Inc. (CARM).